CureVac Taps Celonic For COVID-19 Vaccine Production

CureVac BV CVAC has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV.
The commercial supply agreement includes manufacturing of the mRNA drug substance and LNP formulation of the bulk drug product at Celonic's manufacturing facility in Heidelberg, Germany.
In total, Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.
Under the terms of the initial agreement, technology and knowledge transfer are already underway.
CureVac reaffirms an expected output capacity of its broad European manufacturing network of up to 300 million doses in 2021.
CureVac has entered into several strategic partnerships for the further development, production, and commercialization of CVnCoV.
In January, it signed a collaboration agreement with Bayer regarding CureVac's current CVnCoV currently in Phase 2b/3.
In February, CureVac and GlaxoSmithKline plc GSK agreed to develop next-generation mRNA vaccines against COVID-19 jointly.
Price Action: CVAC shares are down 0.5% at $86.2 in premarket trading on the last check Tuesday.